GlassScriptPhysician profile
Steve Shah
NPI 1073133765
$1,714.66
in general payments reported to CMS, 2019-2025
20 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $511 · 2024: $542 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $23.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.84 |
| Education | $23.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.59 | 2023-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $276.31 | 2024-2025 | |
| Novo Nordisk INC | $227.83 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $156.38 | 2025 | Endurant Iis |
| Exact Sciences Corporation | $121.87 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Astrazeneca Pharmaceuticals LP | $81.48 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lundbeck LLC | $67.66 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $58.94 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $57.10 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $44.38 | 2023-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.70 | 2023-2025 | Caplyta |
| Janssen Biotech, INC. | $32.50 | 2025 | Darzalex, Tecvayli, Talvey |
| Opko Pharmaceuticals, LLC | $23.82 | 2024 | Rayaldee |
| Pfizer INC. | $22.36 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.97 | 2025 | Shingrix, Bexsero, Arexvy |
| Novartis Pharmaceuticals Corporation | $18.81 | 2024 | |
| Insulet Corporation | $17.22 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $16.73 | 2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $15.72 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.